A workshop on “The Interface of Pancreatic Cancer with Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities” was held by the National Institute of Diabetes and Digestive and Kidney Diseases on October 12, 2017. The purpose of the workshop was to explore the relationship and possible mechanisms of the increased risk of pancreatic ductal adenocarcinoma (PDAC) related to diabetes, the role of altered intracellular energy metabolism in PDAC, the mechanisms and biomarkers of diabetes caused by PDAC, the mechanisms of the increased risk of PDAC associated with obesity, and the role of inflammatory events and mediators as contributing causes of the development of PDAC. Workshop faculty reviewed the state of the current knowledge in these areas and made recommendations for future research efforts. Further knowledge is needed to elucidate the basic mechanisms contributing to the role of hyperinsulinemia, hyperglycemia, adipokines, and acute and chronic inflammatory events on the development of PDAC.
From the *Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC; †Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; ‡Department of Immunotechnology, University of Lund, Lund, Sweden; §Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN; ∥Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom; ¶Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Ohio State University, Columbus, OH; #Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles; and **Departments of Pathology and Medicine, Stanford University, Palo Alto, CA; ††Department of Surgery, Baylor College of Medicine, Houston, TX; ‡‡Division of Gastroenterology, Department of Medicine, Stanford University, Palo Alto, CA; §§Departments of Developmental Biology and Internal Medicine, Stanford University, Palo Alto, CA; ∥∥Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN; ¶¶Departments of Cancer Biology and Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX; ##Division of Gastroenterology, Departments of Molecular and Integrative Physiology and Internal Medicine, University of Michigan, Ann Arbor, MI; ***Department of Medicine and Biomedical Sciences, Cedars Sinai Medical Center; and †††Department of Medicine, University of California at Los Angeles, Los Angeles, CA; ‡‡‡Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA; §§§Department of Surgery, Oregon Health and Science University, Portland, OR; ∥∥∥Departments of Oncology and Surgery, Johns Hopkins University, Baltimore, MD; and ¶¶¶Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center; and ###Department of Molecular Physiology & Biophysics, Vanderbilt University, VA Tennessee Valley Healthcare, Nashville, TN.
Received for publication February 3, 2018; accepted February 20, 2018.
Address correspondence to: James L. Abbruzzese, MD, Duke University Medical Center, 10 Bryan Searle Dr, Seeley G. Mudd Bldg, Room 440, Duke University Medical Center, Durham, NC 27710 (e-mail: firstname.lastname@example.org).
Supported in part by Public Health Services and other grants: P50 CA014236 (to J.L.A.), P01 CA163200 (to G.E.), R01 CA075059 and U01 DK 108323 (to M.K.), R01 DK060694 (to A.R.), Pancreatic Cancer UK, Pancreatic Cancer Action Network and the NIHR Clinical Research Network grants (to E.C), and a Pancreatic Cancer Action Network/AACR Pathway to Leadership award 13-70-25-LYSS (to C.A.L.).
Logistical support was provided by the Scientific Consulting Group, Inc, and by Mr Mark Dennis. This workshop was endorsed by the Consortium for the Study of Pancreatitis, Diabetes, and Pancreatic Cancer supported by the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases.
The authors declare no conflict of interest.